This chemical is primarily utilized in the field of medicinal chemistry for the development of targeted therapeutic agents. It serves as a key intermediate in the synthesis of proteolysis-targeting chimeras (PROTACs), which are innovative molecules designed to degrade specific disease-causing proteins within cells. Its structure is particularly valuable in creating compounds that can bind to both the target protein and an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of the protein. This approach is being actively explored for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune conditions. Additionally, its role in drug discovery extends to optimizing pharmacokinetic properties and enhancing the efficacy of small-molecule drugs.